JNCCN 360 - NSCLC - Ongoing CE Activities

Editor:

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Ongoing CE Activities

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC

A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs Placebo for Patients With Tumors Harboring the ALK Fusion Protein

A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1 and 4 cm:

A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations

ALK- or ROS1-Rearranged NSCLC: Effectively Integrating Precision Medicine into Patient-Centered Care

Integrating the Latest Evidence Into KRAS Molecular Testing for NSCLC

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 1 of a 4-Part Series

Non-Small Cell Lung Cancer: Management of Patients With Resectable Disease

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

Sections

NCCN Resources

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.